General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Marcan Pharmaceuticals Inc.
Indication:
Wilson's Disease
Last updated March 25, 2022
Status:
Concluded with an LOI
Manufacturer:
Organon Canada Inc.
Indication:
Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma
Last updated March 16, 2022
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Light chain amyloidosis (AL), newly diagnosed in adult patients (in combination with bortezomib, cyclophosphamide, and dexamethasone)
Last updated March 11, 2022
Status:
Concluded without agreement
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Rheumatoid Arthritis
Last updated March 10, 2022
Insulin pumps and pump supplies (Insulin pumps and pump supplies)
Status:
Concluded with an LOI
Manufacturer:
Ypsomed Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated March 8, 2022
Insulin pumps and pump supplies (Insulin pumps and pump supplies)
Status:
Concluded with an LOI
Manufacturer:
Medtronic Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated March 8, 2022
Status:
Concluded with an LOI
Manufacturer:
Jamp Pharma Corporation
Indication:
Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Last updated March 3, 2022
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Multiple Sclerosis, Relapsing-Remitting
Last updated March 2, 2022
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Last updated March 1, 2022
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis
Last updated February 28, 2022